The anti-abortion movement's patience with the Food and Drug Administration (FDA) is wearing thin following the agency’s recent approval of a second generic version of mifepristone, one of two drugs taken for a medication abortion.

President Trump repeatedly pledged during the campaign last year that he would leave abortion policy to the states, but anti-abortion advocates and lawmakers have been pushing him to go further and sharply restrict the availability of mifepristone.

So far, that hasn’t happened.

A letter sent to a group of GOP state attorneys general in September confirmed that the FDA was reviewing evidence about the safety of mifepristone to investigate how it can be safely dispensed.

“This Administration will ensure that women’s health is properly protected by thoroughly i

See Full Page